A TheraSphere® Advanced Dosimetry Retrospective Global Study in HCC

CompletedOBSERVATIONAL
Enrollment

209

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

December 1, 2020

Study Completion Date

December 1, 2020

Conditions
Hepatocellular Carcinoma
Interventions
DEVICE

TheraSphere

Patients who had received TheraSphere

Trial Locations (14)

1011

Centre Hospitalier Universitaire Vaudois, Lausanne

12713

King Faisal Hospital, Riyāḑ

20133

Foundation IRCCS Istituto Nazionale Tumori, Milan

34093

Istanbul university Istanbul medical school, Fatih

34381

Florence Nightingale, Şişli

44229

Centre Eugene Marquis, Rennes

45122

Universitätsklinikum Essen, Essen

46202

Indiana University School of Medicine, Indianapolis

63110

Washington University in St. Louis, School of Medicine, Saint Louis

94305-5642

Stanford University Medical Center, Stanford

32610-0374

University of Florida College of Medicine, Gainesville

60611-2927

Northwestern Memorial Hospital, Robert H Lurie Comprehensive Cancer Center, Chicago

77030-3722

The University of Texas MD Anderson Cancer Center, Houston

3509 GA

Universitair Medisch Centrum Utrecht, Utrecht

Sponsors
All Listed Sponsors
collaborator

Biocompatibles UK Ltd

INDUSTRY

lead

Boston Scientific Corporation

INDUSTRY